Abstract
Background and research question:
Loss of exclusivity of oncology drugs causes an important drop in their price due to the marketing of generic medicines. In this article we study how the price of certain oncology drugs evolves throughout time after the loss of their patent, both in terms of the notified price and at a level of the public tenders for the purchase of medicines.
Methods:
The variation in the price of oral oncology drugs was assessed from the public information provided by the Interministerial Medicinal Products Pricing Committee (Comisión Interministerial de Precios de los Medicamentos, CIPM) and the data from public tenders for the purchase of medicines.
Results:
The data show a significant drop in price of the medicines assessed after the expiry of their patent, both at a notified price level (70% of average drop in price in 2.6 years) and at the level of the public tenders (drops exceeding 90% in a year for the most innovative drugs).
Discussion:
The drop in the price of the oncology drugs after the expiry of their patent is seen in all the medicines assessed. The trends seen allow to predict the evolution of the price of another innovative medicine that is nearing the expiry of its patent (Lenalidomide), with an expected drop in price by 90% with respect to the current price of the innovative drug.
Keywords: Generic medicines, Lenalidomide, Oncology drugs
Introduction
Currently, cancer is the second cause of death in Spain, with 26.4% of the deceases in 2018 related to this group of diseases (112,714 deaths). Despite the alarming and high figures, the impact of these diseases decreases progressively. In fact, mortality due to cancer in Spain has been dropping steadily in the last years (1). This drop in the mortality caused by cancer is due, among other causes, to the appearance of new therapeutic innovations that allow to improve the prognosis of the oncology patients.
Patents protect and stimulate the development of new therapeutic innovations by the exclusive marketing rights provided by the protection guaranteed by the patents. Nevertheless, once this period has ended with the expiry of the patent, the price of the medicines drops because of the appearance of generic medicines (Gx). As the Spanish Generic Medicines Association (Asociación Española de Medicamentos Genéricos, AESEG) underlines, the drop in price caused by the appearance of the generic medicines and approved by the Interministerial Medicinal Products Pricing Committee (Comisión Interministerial de Precios de los Medicamentos, CIPM) fluctuates between 40% and 60% with respect to the cost of the brand drug (2). In the case of drugs for hospital use, as is the case of the oncology drugs, their purchase is carried out through a public tender process that favours competition between different suppliers (in this case, pharmaceutical companies). Tender process causes important drops in price that are greater than those seen in the approved prices notified by the CIPM.
Price drops allow to free public resources, optimising the health expenditure, therefore being able to relocate resources to other areas, so that the sustainability of the system is favoured, and the medical care improves (2).
This is especially relevant in the field of oncology, as highlighted in a recent study by Cheung et al (3). This study concludes that oncology generic medicines could significantly modify the cost-effectiveness and cost-utility ratios of the studied treatments.
The objective of this report is to analyse the influence of the generic medicines on the evolution of the price of oral oncology drugs after the loss of exclusive marketing rights, with the aim of showing the impact of generic medicines on the drop in price of oncology drugs and, therefore, on the drop in price of oncology treatments, in a quick and powerful way. Likewise, we look for the identification of trends in these drops in price that allow assessing the evolution in the price of oral oncology treatments that are nearing the end of their exclusive marketing rights period.
Methodology
Selection of drugs
With the intention of delimiting the analysis to a manageable sample size, oral oncology treatments, recommended for monotherapy or in combination with other drugs, whose patent had expired and that have generic medicines in the market, so there is a price competition that allows to see its evolution after the loss of their exclusive marketing rights, were chosen.
According to the previously mentioned criteria and using the BotPlus drug databases and the Medicine Online Information Centre (Centro de Información Online de Medicamentos, CIMA) of the Spanish Agency of Medicine and Medical Devices (Agencia Española de Medicamentos y Productos Sanitarios), we have selected the eight following drugs: Vinorelbine, Capecitabine, Imatinib, Pemetrexed, Erlotinib, Dasatinib, Gefitinib and Everolimus.
Sources of information
For each of these drugs, the evolution of the “List price” (LP) and/or the tender price (TP) was analysed in the case of public tenders, using the following data sources:
Minutes and Agreements of the CIPM: Used to decide the authorised LPs for the initial marketing of the innovative drugs (Supplementary tables S I to S IX), as well as the first authorised LP for each generic medicine. When gathering the LPs of the generic medicines, we have only borne in mind the generic medicines with the lowest LP, the presentation that provides the most advantageous economic offer.
BotPlus: It is used for obtaining the current LPs of the different analysed drugs (both innovative and generic) as well as their marketing authorisation dates.
Public tenders: A gathering of public tender data provided by Acobur (Advice in public health contracting) has been carried out regarding the purchase of each medicine during the years after and before the loss of the exclusive marketing rights, including tenders from hospitals and the healthcare services of different regions to ensure a representative sample.
Analysis of the evolution of the prices
From the information gathered, a double analysis was carried out. On the one hand, the variations in the LPs experienced by each drug as a function of the time passed from the LPs were approved for each generic medicine presentation. The percent decrease in the notified LP of each new generic medicine with respect to the innovative drug was calculated, and their evolution throughout time was analysed. On the other hand, the evolution of the prices obtained in the public tenders of the drugs and the TPs throughout time was analysed, focusing on the period before and after the loss of the exclusive marketing rights and the appearance of generic medicines, being therefore able to see decreases in the TPs.
Prediction of the decreases in price as a function of the trends seen
From the trends seen in this analysis, the possible evolution in the price of an oncologic drug similar to those included in the analysis, as in the case of Revlimid® (Lenalidomide), an innovative drug by Bristol Myers Squibb, whose patent expires in the first quarter of 2022 (4), will be estimated. To strengthen the prediction, we have relied on the advice of hospital pharmacists with a view to having in mind their knowledge regarding the evolution of the prices of drugs.
Results
Evolution of the LPs notified after the appearance of generic medicines
The analysis of the evolution throughout time of the notified LPs shows how the analysed drugs experience an average initial drop in price by 46%, although the drop increases with time, as we can see in Table I, with an average maximum decrease in the notified LP by 70% in an average interval of 2.6 years.
TABLE I -.
Maximum drops in the notified LPs experienced by the analysed oncologic drugs, first drops experienced, and time intervals passed until reaching the minimum notified LP since the approval of the LP of the first generic medicine
| Drug | Patent expiration Date | First descent notified LP | Maximum descent notified LP | Years to minimum LP |
|---|---|---|---|---|
| Vinorelbine | Not available | −37% | −56% | 4.3 |
| Capecitabine | 14/12/2013 | −39% | −68% | 1.9 |
| Imatinib | 01/12/2016 | −40% | −97% | 4.6 |
| Pemetrexed | 10/06/2021 | −40% | −45% | 4.4 |
| Erlotinib | 01/03/2020 | −42% | −74% | 1.1 |
| Dasatinib | 01/11/2019 | −69% | −70% | 1.3 |
| Gefitinib | 01/09/2019 | −40% | −84% | 1.1 |
| Everolimus | 17/01/2019 | −58% | −66% | 1.7 |
LP = list price.
There is not a homogeneity in the decreases in the LPs seen in each of the analysed drugs, and we can find very dissimilar cases, such as that of Imatinib, that reaches a drop by 97% in 4.6 years, versus the rapid drop in the notified LP of Gefitinib of 84% in 1.1 years.
The fact that the four most recently approved drugs (Erlotinib, Dasatinib, Gefitinib and Everolimus) experience a drop in their LP greater than 65% in 1 year must be highlighted. The data suggest that the process of the drop in the LP as a consequence of the marketing of generic medicines has accelerated in the last years, both in terms of magnitude and time (an average of 1.3 years to reach the maximum drop versus the 3.8 years in the group of older drugs).
The presented data show how the marketing of generic drugs after the loss of the patent of the innovative medicine causes a decrease in the notified LP of the analysed oncologic drugs. Nevertheless, the hospital medicines are purchased through public tenders in which the LP only acts as a guide and a maximum price ceiling. This entails that the decrease in the TP due to the competition between pharmaceutical companies can be, in real-world conditions, much lower than the notified LP.
Evolution of the TPs in public tenders after the appearance of generic drugs
As previously highlighted, the analysed drugs are medicines used in hospitals. Their purchase is carried out through tenders that, due to their own nature, generate a competition between pharmaceutical companies when presenting an offer that results in a price war, being the TP, and not the LP, the price paid by the healthcare centres.
The evolution of the TPs has been analysed after the loss of the exclusive marketing rights of the following drugs: Capecitabine, Imatinib, Erlotinib, Gefitinib and Everolimus. The analysis of the tenders in the case of Dasatinib and Pemetrexed could not be carried out due to the recent loss of their patent, this preventing the generic medicines pharmaceutical companies from being able to participate in public tenders when this study was carried out. It was also not possible to study the evolution of the TP of Vinorelbine after the loss of its exclusive marketing rights. Vinorelbine lost its exclusive marketing rights in 2009 and the database used to obtain the information regarding tenders only provides information from 2010. Therefore, the study of these data does not allow to see the real drop in price after the marketing of generic medicines.
The analysis of the tenders of the most innovative oncology drugs (excluding chemotherapy, as in the case of capecitabine) shows two differentiated trends (Fig. 1). Everolimus dropped its TP by 42% versus LP in the first year after the loss of its patent. This could be due to this drug only losing its exclusive marketing rights regarding the indications of advanced breast cancer and neuroendocrine tumours but not in renal cell carcinoma. Nevertheless, this effect disappears after the first year, with a drop of 85% in TP versus LP during the second year after the partial loss of its exclusive marketing rights.
Fig. 1 -.
Drops in the tender price in public bids experienced by the analysed oncologic drugs during the first (blue bars) and second (orange bars) years after the loss of the exclusive marketing rights.
Imatinib, Erlotinib and Gefitinib present common trends (Fig. 1). These three drugs experience a drop in their TP greater than 90% versus LP in the first year after the loss of their exclusive marketing rights. Capecitabine, another analysed drug, dropped its TP by 89% versus LP after its first year without exclusive marketing rights (Fig. 1). Nevertheless, because it is a chemotherapeutic treatment, it is considered that it must be analysed separately from Imatinib, Erlotinib and Gefitinib.
All the assessed drugs experience a pronounced and significant drop in their TP after the loss of the exclusive marketing rights, in a period of 1 year, decreases exceeding 80%, reaching figures above 90% in innovative drugs. Because of this, it seems that the savings in costs generated by the marketing of generic medicines are even higher than that deduced from the notified LPs.
Prediction of the evolution of the price of Revlimid® (Lenalidomide)
As mentioned in the methodology section, the analysed data and price trends allow to estimate the LP of other drugs that are nearing the marketing of generic medicines, as in the case of Revlimid® (Lenalidomide), by BMS, whose patent expires in the first quadrimester of 2022 (4). This drug is recommended for the treatment of oncohaematologic disorders such as multiple myeloma, mantle cell lymphoma and follicular lymphoma, as well as myelodysplastic syndromes, reaching in 2020 global sales for USD12,100 million. Revlimid® will lose its exclusive marketing rights in March 2022.
There are currently 20 Lenalidomide generic medicines authorised in Spain; 14 of these 20 Lenalidomide generics have an approved LP (Tab. II), and therefore they would be ready for their marketing after the loss of the exclusive marketing rights. Five generics with a decrease of –59% and the other generics show a notified LP that is 65% lower than the LP notified for the innovative medicine Revlimid®. It should be noted that in some cases, such as Reddy’s Pharma, it has requested a voluntary reduction in its generic medicine price, going from the initial –59% to –65%. In case of not changing the LP of Revlimid® until the loss of the exclusive marketing rights, these data entail a great decrease in the LP that is greater than that seen in other analysed drugs.
TABLE II -.
Analysis of the evolution of the LP of the different generic Lenalidomide medicines approved in Spain with respect to the innovative drug
| Drug type and company | CIPM date | Marketing authorisation date | CIPM LP (€/mg)* | Interval since 1st Gx LP approval by CIPM (years) | Price difference vs innovative price | Price difference vs 1st Gx LP |
|---|---|---|---|---|---|---|
| Innovative (BMS) | 25/05/2007 | 14/06/2007 | 11.518 | NA | NA | NA |
| Generic 1 (Cipla) | 14/10/2020 | 10/03/2020 | 4.678 | 0 | −59% | NA |
| Generic 2 (Accord) | 28/02/2021 | 27/11/2020 | 4.678 | 0.4 | −59% | 0% |
| Generic 3 (Reddy Pharma) | 01/12/2020 | 01/12/2020 | 4.678 | 0.1 | −59% | 0% |
| Generic 4 (Stada) | 27/11/2020 | 20/03/2021 | 4.678 | 0.1 | −59% | 0% |
| Generic 5 (Kern) | 31/03/2021 | 01/10/2020 | 4.678 | 0.5 | −59% | 0% |
| Generic 6 (Krka) | 31/05/2021 | 20/03/2021 | 4.678 | 0.6 | −59% | 0% |
| Generic 7 (Viso) | 30/06/2021 | 09/02/2021 | 4.678 | 0.7 | −59% | 0% |
| Generic 8 (Teva) | 31/07/2021 | 01/08/2019 | 4.678 | 0.8 | −59% | 0% |
| Generic 9 (Fresenius) | 31/10/2021 | 09/02/2021 | 3.977 | 1.0 | −65% | −15% |
| Generic 10 (Mylan) | 31/10/2021 | 25/06/2021 | 3.977 | 1.0 | −65% | −15% |
| Generic 11 (Sandoz) | 31/10/2021 | 09/02/2021 | 3.977 | 1.0 | −65% | −15% |
| Generic 12 (Aurovitas) | 30/11/2021 | 01/10/2021 | 3.977 | 1.1 | −65% | −15% |
| Generic 13 (Sun) | 31/12/2021 | 01/10/2021 | 3.977 | 1.2 | −65% | −15% |
| Generic 14 (Tarbis) | 31/12/2021 | 01/09/2020 | 3.977 | 1.2 | −65% | −15% |
* In the case of the innovative drug, the LP indicated is the one prior to the marketing of the f irst generic, not the initial LP.
CIPM = Comisión Interministerial de Precios de los Medicamentos; Gx = generic medicines; LP = list price.
In the case of the drug tenders, it is reasonable to predict that Lenalidomide will follow the same pattern seen in other analysed oncologic drugs, with a decrease in their TP by 90% during their first year of marketing as generic medicines. Hospital pharmacists consulted on the expected trend of Lenalidomide in drug tenders have stated that it is expectable that the TP of Lenalidomide in tenders decreases by approximately 75%, at least with respect to its current price, in the first year.
Conclusions
The data analysed in this study show that the marketing of generic medicines causes a significant drop in the notified LP of the drug. This drop is especially quick in the TP of the bids, that experience a fall by 90% in a year with respect to the LP of the innovative drug.
In 2022, Lenalidomide (Revlimid®), whose global invoicing was USD12,100 million, will lose its patent. There are already nine approved generic medicines with an LP 65% lower than that of Revlimid®. Voluntary drops such as that applied by Reddy’s Pharma in its generic could suggest a rapid drop in the price of generic Lenalidomide due to competition between different laboratories.
The analysis carried out in this report of tenders of generic oral oncologic drugs together with the interviews made to hospital pharmacists allow to consider that the marketing of generic Lenalidomide medicines will entail a drop by 90% in the LP of Revlimid®.
Disclosures
Conflict of interest: The authors declare no conflict of interest.
Financial support: This research has been possible thanks to Incyte Biosciences Iberia, which has financed the project and the publication of the manuscript.
Authors contribution: All authors contributed equally to this manuscript.
Data regarding the list price (LP) and dates of approval of the drugs
Table S I.
Analysis of the evolution of the LP of the different generic Vinorelbine medicines approved in Spain with respect to the innovative drug.
| Drug type & company | CIPM approval date | Marketing authorization date | CIPM LP (€/mg)* | Interval since 1st Gx approval by CIPM (years) | Price difference vs innovative price | Price difference vs 1st Gx approved by CIPM |
|---|---|---|---|---|---|---|
| Innovative (Pierre Fabre) | 20/01/2001 | 01/07/1993 | 1.43 | NA | NA | NA |
| Generic 1 (Actavis) | 12/03/2009 | 04/11/2008 | 0.9 | 0 | -37% | NA |
| Generic 2 (IPS Pharma) | 29/11/2010 | 09/07/2010 | 0.69 | 1.7 | -52% | -23% |
| Generic 3 (Sandoz) | 30/06/2013 | 30/04/2009 | 0.63 | 4.3 | -56% | -30% |
| Generic 4 (Accord) | 28/02/2018 | 16/11/2007 | 0.63 | 9.0 | -56% | -30% |
* In the case of the innovative drug, the authorized LP at the time of marketing of the first generic drug is indicated.
Table S II.
Analysis of the evolution of the LP of the different generic Paclitaxel medicines approved in Spain with respect to the innovative drug.
| Drug type & company | CIPM approval date | Marketing authorization date | CIPM LP (€/mg)* | Interval since 1st Gx approval by CIPM (years) | Price difference vs innovative price | Price difference vs 1st Gx approved by CIPM |
|---|---|---|---|---|---|---|
| Innovador (BMS) | 01/10/2006 | 01/11/1999 | 4.27 | NA | NA | NA |
| Generic 1 (Merck) | 08/11/2007 | 30/05/2007 | 1.87 | 0 | -56% | NA |
| Generic 2 (GP-Pharm) | 09/10/2008 | 05/05/2008 | 1.87 | 0.9 | -56% | 0% |
| Generic 3 (Stragen) | 07/05/2009 | 15/12/2008 | 1.35 | 1.5 | -68% | -28% |
| Generic 4 (Accord) | 29/02/2012 | 27/10/2011 | 1.31 | 4.3 | -69% | -30% |
| Generic 5 (Swan Pond) | 30/06/2012 | 14/02/2012 | 1.31 | 4.6 | -69% | -30% |
| Generic 6 (Fresenius) | 31/07/2012 | 15/10/2010 | 1.31 | 4.7 | -69% | -30% |
| Generic 7 (Cipla) | 31/12/2015 | 09/10/2015 | 1.31 | 8.2 | -69% | -30% |
*1 In the case of the innovative drug, the most recent obtained (October 2006) is taken as LP.
*2 In the case of the innovative drug, the authorized LP at the time of marketing of the first generic is indicated.
Table S III.
Analysis of the evolution of the LP of the different generic Capecitabine medicines approved in Spain with respect to the innovative drug.
| Drug type & company | CIPM approval date | Marketing authorization date | CIPM LP (€/mg)* | Interval since 1st Gx approval by CIPM (years) | Price difference vs innovative price | Price difference vs 1st Gx approved by CIPM |
|---|---|---|---|---|---|---|
| Innovador (Roche) | 26/05/2008 | 02/02/2001 | 0.0057 | NA | NA | NA |
| Generic 1 (Actavis) | 30/04/2013 | 21/01/2013 | 0.0035 | 0 | -39% | NA |
| Generic 2 (Fresenius) | 31/07/2013 | 25/03/2013 | 0.0023 | 0.3 | -60% | -34% |
| Generic 3 (Kern) | 30/11/2013 | 25/06/2012 | 0.0023 | 0.6 | -60% | -34% |
| Generic 4 (Combino) | 30/11/2013 | 17/09/2013 | 0.0023 | 0.6 | -60% | -34% |
| Generic 5 (Sun) | 31/12/2013 | 23/07/2013 | 0.0023 | 0.7 | -60% | -34% |
| Generic 6 (Cipla) | 31/03/2015 | 01/12/2014 | 0.0018 | 1.9 | -68% | -49% |
| Generic 7 (Normon) | 30/11/2015 | 28/07/2015 | 0.0018 | 2.6 | -68% | -49% |
| Generic 8 (Labosuan) | 29/02/2016 | 11/09/2015 | 0.0018 | 2.8 | -68% | -49% |
| Generic 9 (Fair-Med) | 30/04/2016 | 07/10/2015 | 0.0018 | 3.0 | -68% | -49% |
* In the case of the innovative drug, the authorized LP at the time of marketing of the first generic drug is indicated.
Table S IV.
Analysis of the evolution of the LP of the different generic Imatinib medicines approved in Spain with respect to the innovative drug.
| Drug type & company | CIPM approval date | Marketing authorization date | CIPM LP (€/mg)* | Interval since 1st Gx approval by CIPM (years) | Price difference vs innovative price | Price difference vs 1st Gx approved by CIPM |
|---|---|---|---|---|---|---|
| Innovative (Novartis) | 25/05/2007 | 07/11/2001 | 0.20 | NA | NA | NA |
| Generic 1 (Aurovitas) | 30/06/2016 | 26/01/2016 | 0.12 | 0 | -40% | NA |
| Generic 2 (Accord) | 30/06/2016 | 28/03/2016 | 0.118 | 0.0 | -40% | 0% |
| Generic 3 (Sandoz) | 30/07/2016 | 31/03/2016 | 0.118 | 0.1 | -40% | 0% |
| Generic 4 (Teva) | 30/07/2016 | 01/06/2016 | 0.118 | 0.1 | -40% | 0% |
| Generic 5 (Ranbaxy) | 31/10/2016 | 14/07/2015 | 0.118 | 0.3 | -40% | 0% |
| Generic 6 (Normon) | 31/10/2016 | 05/07/2016 | 0.118 | 0.3 | -40% | 0% |
| Generic 7 (Ferrer) | 30/11/2016 | 16/03/2015 | 0.118 | 0.4 | -40% | 0% |
| Generic 8 (Krka) | 30/11/2016 | 19/09/2016 | 0.118 | 0.4 | -40% | 0% |
| Generic 9 (Cipla) | 31/12/2016 | 29/09/2016 | 0.118 | 0.5 | -40% | 0% |
| Generic 10 (Kern) | 31/12/2016 | 17/10/2016 | 0.118 | 0.5 | -40% | 0% |
| Generic 11 (Farmalider) | 30/04/2017 | 11/03/2016 | 0.118 | 0.8 | -40% | 0% |
| Generic 12 (Fresenius) | 30/04/2017 | 10/01/2017 | 0.118 | 0.8 | -40% | 0% |
| Generic 13 (Viso) | 01/09/2017 | 26/01/2016 | 0.118 | 1.2 | -40% | 0% |
| Generic 14 (Reddy) | 30/06/2019 | 27/07/2018 | 0.011 | 3.0 | -94% | -91% |
| Generic 15 (Labosuan) | 31/07/2019 | 01/03/2019 | 0.011 | 3.1 | -94% | -91% |
| Generic 16 (Tarbis) | 31/01/2021 | 10/06/2020 | 0.006 | 4.6 | -97% | -95% |
| Generic 17 (Qilu) | 31/05/2021 | 26/01/2021 | 0.006 | 4.9 | -97% | -95% |
* In the case of the innovative drug, the authorized LP at the time of marketing of the first generic drug is indicated.
Table S V.
Analysis of the evolution of the LP of the different generic Pemetrexed medicines approved in Spain with respect to the innovative drug.
| Drug type & company | CIPM approval date | Marketing authorization date | CIPM LP (€/mg)* | Interval since 1st Gx approval by CIPM (years) | Price difference vs innovative price | Price difference vs 1st Gx approved by CIPM |
|---|---|---|---|---|---|---|
| Innovative (Lilly) | 08/07/2008 | 20/09/2004 | 2.400 | NA | NA | NA |
| Generic 1 (Sandoz) | 30/04/2016 | 18/09/2015 | 1.440 | 0 | -40% | NA |
| Generic 2 (Ferrer) | 30/11/2016 | 01/07/2016 | 1.440 | 0.6 | -40% | 0% |
| Generic 3 (Fresenius) | 31/12/2016 | 22/07/2016 | 1.440 | 0.7 | -40% | 0% |
| Generic 4 (Ranxaby) | 31/07/2017 | 17/04/2017 | 1.440 | 1.3 | -40% | 0% |
| Generic 5 (Prasfarma) | 31/12/2017 | 01/06/2017 | 1.440 | 1.7 | -40% | 0% |
| Generic 6 (Krka) | 30/11/2019 | 22/05/2018 | 1.440 | 3.6 | -40% | 0% |
| Generic 7 (Accord) | 30/09/2020 | 18/01/2016 | 1.332 | 4.4 | -45% | -7% |
| Generic 8 (Fresenius) | 31/01/2021 | 10/06/2020 | 1.332 | 4.8 | -45% | -7% |
* In the case of the innovative drug, the authorized LP at the time of marketing of the first generic drug is indicated.
Table S VI.
Analysis of the evolution of the LP of the different generic Erlotinib medicines approved in Spain with respect to the innovative drug.
| Drug type & company | CIPM approval date | Marketing authorization date | CIPM LP (€/mg)* | Interval since 1st Gx approval by CIPM (years) | Price difference vs innovative price | Price difference vs 1st Gx approved by CIPM |
|---|---|---|---|---|---|---|
| Innovative (Roche) | 25/05/2007 | 19/09/2005 | 0.553 | NA | NA | NA |
| Generic 1 (Teva) | 25/04/2019 | 24/07/2018 | 0.319 | 0 | -42% | NA |
| Generic 2 (Hetero) | 29/02/2020 | 21/09/2018 | 0.319 | 0.8 | -42% | 0% |
| Generic 3 (Cipla) | 31/05/2020 | 09/01/2020 | 0.143 | 1.1 | -74% | -55% |
* In the case of the innovative drug, the authorized LP at the time of marketing of the first generic drug is indicated.
Table S VII.
Analysis of the evolution of the LP of the different generic Dasatinib medicines approved in Spain with respect to the innovative drug.
| Drug type & company | CIPM approval date | Marketing authorization date | CIPM LP (€/mg)* | Interval since 1st Gx approval by CIPM (years) | Price difference vs innovative price | Price difference vs 1st Gx approved by CIPM |
|---|---|---|---|---|---|---|
| Innovative (BMS) | 07/02/2009 | NA | 1.559 | NA | NA | NA |
| Generic 1 (Teva) | 30/10/2019 | 01/05/2019 | 0.49 | 0 | -69% | 0% |
| Generic 2 (Stada) | 28/02/2021 | 01/07/2020 | 0.472 | 1.3 | -70% | -4% |
* In the case of the innovative medicine, the authorized PVL at the time of marketing of the first generic drug is indicated.
Table S VIII.
Analysis of the evolution of the LP of the different generic Gefitinib medicines approved in Spain with respect to the innovative drug.
| Drug type & company | CIPM approval date | Marketing authorization date | CIPM LP (€/mg)* | Interval since 1st Gx approval by CIPM (years) | Price difference vs innovative price | Price difference vs 1st Gx approved by CIPM |
|---|---|---|---|---|---|---|
| Innovative (AstraZeneca) | 01/02/2010 | 24/06/2009 | 0.273 | NA | NA | NA |
| Generic 1 (Accord) | 30/06/2019 | 28/03/2019 | 0.164 | 0 | -40% | NA |
| Generic 2 (Aristo) | 30/06/2019 | 19/11/2018 | 0.164 | 0 | -40% | 0% |
| Generic 3 (Mylan) | 30/06/2019 | 02/01/2019 | 0.164 | 0 | -40% | 0% |
| Generic 4 (Reig Jofre) | 30/06/2019 | 08/02/2019 | 0.164 | 0 | -40% | 0% |
| Generic 5 (Sandoz) | 30/06/2019 | 28/12/2018 | 0.164 | 0 | -40% | 0% |
| Generic 6 (Teva) | 30/06/2019 | 21/02/2019 | 0.164 | 0 | -40% | 0% |
| Generic 7 (Qilu) | 31/08/2019 | 08/04/2019 | 0.164 | 0.2 | -40% | 0% |
| Generic 8 (Cipla) | 31/07/2020 | 14/01/2020 | 0.043 | 1.1 | -84% | -74% |
* In the case of the innovative medicine, the authorized LP at the time of marketing of the first generic drug is indicated.
Tabla S IX.
Analysis of the evolution of the LP of the different generic Everolimus medicines approved in Spain with respect to the innovative drug.
| Drug type & company | CIPM approval date | Marketing authorization date | CIPM LP (€/mg)* | Interval since 1st Gx approval by CIPM (years) | Price difference vs innovative price | Price difference vs 1st Gx approved by CIPM |
|---|---|---|---|---|---|---|
| Innovative (Novartis) | 08/07/2010 | 17/09/2009 | 16.89 | NA | NA | NA |
| Generic 1 (Stada) | 30/11/2018 | 01/07/2018 | 7.094 | 0 | -58% | NA |
| Generic 2 (Accord) | 28/02/2019 | 01/10/2018 | 7.094 | 0.2 | -58% | 0% |
| Generic 3 (Krka) | 28/02/2019 | 01/10/2018 | 7.094 | 0.2 | -58% | 0% |
| Generic 4 (Reddy Pharma) | 28/02/2019 | 01/09/2018 | 7.094 | 0.2 | -58% | 0% |
| Generic 5 (Sandoz) | 30/06/2019 | 01/03/2019 | 7.094 | 0.6 | -58% | 0% |
| Generic 6 (Tamarang) | 29/02/2020 | 01/05/2019 | 5.777 | 1.2 | -66% | -19% |
| Generic 7 (Mylan) | 31/05/2020 | 09/01/2020 | 5.777 | 1.5 | -66% | -19% |
| Generic 8 (Medicare) | 31/07/2020 | 19/09/2019 | 5.777 | 1.7 | -66% | -19% |
* In the case of the innovative medicine, the authorized LP at the time of marketing of the first generic drug is indicated.
Data regarding the list price (LP) and dates of approval of the drugs
Public tender data
Table S X.
Tenders identified for the Capecitabine drug between years 2012 and 2016.
| ORGANISM | BATCH DATA | AWARD DATA | |||||
|---|---|---|---|---|---|---|---|
| Region | Convening body | Product requested by the agency | Volume for tender’s duration (mg) | Maximum bid price (€/mg) | Awardee | Award price (€/mg) | Award date |
| Madrid | Servicio Madrileño de Salud | Capecitabina | 1,334,512,000 | 0.0004 | ACCORD HEALTHCARE | 0.0004 | 27/03/2017 |
| Madrid | Servicio Madrileño de Salud | Capecitabina | 1,334,512,000 | 0.0004 | CIPLA EUROPE | 0.0004 | 27/03/2017 |
| Baleares | Servicio de Salud de las Islas Baleares | Capecitabina 500mg comprimidos | 225,000,000 | 0.0004 | ACCORD HEALTHCARE | 0.0004 | 26/07/2017 |
| Baleares | Servicio de Salud de las Islas Baleares | Capecitabina 500mg comprimidos | 225,000,000 | 0.0004 | CIPLA EUROPE | 0.0004 | 26/07/2017 |
| Cataluña | Consorci de Salut i Atenció Social de Catalunya | CAPECITABINA 150 MG 60 COMPRIMIDOS CUBIERTA PELICULAR | 42,939,300 | 0.0005 | ACCORD HEALTHCARE | 0.0005 | 10/07/2018 |
| Cataluña | Consorci de Salut i Atenció Social de Catalunya | CAPECITABINA 150 MG 60 COMPRIMIDOS CUBIERTA PELICULAR | 42,939,300 | 0.0005 | CIPLA EUROPE | 0.0005 | 10/07/2018 |
| Cataluña | Consorci de Salut i Atenció Social de Catalunya | CAPECITABINA 150 MG 60 COMPRIMIDOS CUBIERTA PELICULAR | 42,939,300 | 0.0005 | LABORATORIOS NORMON | 0.0005 | 10/07/2018 |
| Cataluña | Consorci de Salut i Atenció Social de Catalunya | CAPECITABINA 500 MG 120 COMPRIMIDOS CUBIERTA PELICULAR | 754,828,000 | 0.0004 | ACCORD HEALTHCARE | 0.0004 | 10/07/2018 |
| Cataluña | Consorci de Salut i Atenció Social de Catalunya | CAPECITABINA 500 MG 120 COMPRIMIDOS CUBIERTA PELICULAR | 754,828,000 | 0.0004 | CIPLA EUROPE | 0.0004 | 10/07/2018 |
| Cataluña | Consorci de Salut i Atenció Social de Catalunya | CAPECITABINA 500 MG 120 COMPRIMIDOS CUBIERTA PELICULAR | 754,828,000 | 0.0004 | LABORATORIOS NORMON | 0.0004 | 10/07/2018 |
| Canarias | Servicio Canario de la Salud | CAPECITABINA - CAPECITABINA 150 MG COMPRIMIDOS ORAL | 12,699,000 | 0.0005 | CIPLA EUROPE | 0.0004 | 10/08/2018 |
| Canarias | Servicio Canario de la Salud | CAPECITABINA - CAPECITABINA 500 MG COMPRIMIDOS ORAL | 197,400,000 | 0.0004 | CIPLA EUROPE | 0.0004 | 10/08/2018 |
| Comunidad Valenciana | Generalitat Valenciana. Conselleria de Sanidad Universal y Salud Pública | Capecitabína 500 COMPRIMIDOS | 939,110,000 | 0.0004 | ACCORD HEALTHCARE | 0.0004 | 28/03/2019 |
| Andalucía | Plataforma de Logística Sanitaria de Granada | CAPECITABINA 500MG, COMPRIMIDOS | 81,300,000 | 0.0004 | CIPLA EUROPE | 0.0004 | 24/04/2019 |
| Murcia | Servicio Murciano de Salud | CAPECITABINA ORAL | 378,996,000 | 0.0004 | CIPLA EUROPE | 0.0004 | 28/08/2019 |
| Extremadura | Servicio Extremeño de Salud | Capecitabina 500mg 1 Comprimido | 200,579,500 | 0.0004 | ACCORD HEALTHCARE | 0.0004 | 16/10/2019 |
| Galicia | Servicio Gallego de Salud | Capecitabina (D.O.E.) oral | 869,200,000 | 0.0004 | CIPLA EUROPE | 0.0004 | 20/11/2019 |
| Andalucía | Plataforma de Logística Sanitaria de Jaén | CAPECITABINA 500MG, COMPRIMIDOS | 26,000,000 | 0.0006 | CIPLA EUROPE | 0.0004 | 12/03/2020 |
| Cataluña | Institut Català de la Salut (ICS) | CAPECITABINA 150 mg comp | 2,254,500 | 0.0005 | KERN PHARMA | 0.0005 | 22/06/2020 |
| Cataluña | Institut Català de la Salut (ICS) | CAPECITABINA 500 mg comp | 60,930,000 | 0.0004 | KERN PHARMA | 0.0004 | 22/06/2020 |
| País Vasco | Osakidetza-S.v.s. | CAPECITABINA (DOE) COMPRIMIDO DE 150MG | 10,950,000 | 0.0005 | KERN PHARMA | 0.0005 | 26/11/2020 |
| País Vasco | Osakidetza-S.v.s. | CAPECITABINA (DOE) COMPRIMIDO DE 500MG | 185,000,000 | 0.0004 | KERN PHARMA | 0.0004 | 26/11/2020 |
| País Vasco | Osakidetza-S.v.s. | CAPECITABINA (DOE) COMPRIMIDO DE 300MG | 9,000,000 | 0.0004 | KERN PHARMA | 0.0004 | 26/11/2020 |
| Andalucía | Plataforma de Logística Sanitaria de Huelva | CAPECITABINA 500MG, COMPRIMIDOS | 78,240,000 | 0.0006 | LABORATORIOS NORMON | 0.0004 | 30/12/2020 |
| Asturias | Servicio de Salud del Principado de Asturias (Sespa) | CAPECITABINA CAPSULA/COMPRIMIDO | 228,730,000 | 0.0008 | KERN PHARMA | 0.0005 | 03/03/2021 |
| Navarra | Servicio Navarro de Salud - Osasunbidea | Capecitabina 150 mg comprimidos | 7,389,000 | 0.0005 | KERN PHARMA | 0.0005 | 30/03/2021 |
| Navarra | Servicio Navarro de Salud - Osasunbidea | Capecitabina 500 mg comprimidos | 72,780,000 | 0.0004 | KERN PHARMA | 0.0004 | 30/03/2021 |
Table S XI.
Tenders identified for the Imatinib drug between years 2017 and 2021.
| ORGANISM | BATCH DATA | AWARD DATA | |||||
|---|---|---|---|---|---|---|---|
| Region | Convening body | Product requested by the agency | Volume for tender’s duration (mg) | Maximum bid price (€/mg) | Awardee | Award price (€/mg) | Award date |
| Navarra | Servicio Navarro de Salud - Osasunbidea | Imatinib 100 mg. | 178,300 | 0.0987 | NOVARTIS FARMACEUTICA | 0.0907 | 30/06/2017 |
| Navarra | Servicio Navarro de Salud - Osasunbidea | Imatinib 400 mg. | 1,353,600 | 0.0986 | NOVARTIS FARMACEUTICA | 0.0907 | 30/06/2017 |
| Navarra | Servicio Navarro de Salud - Osasunbidea | Imatinib 100 mg | 713,300 | 0.0058 | CIPLA EUROPE | 0.0014 | 30/06/2017 |
| Navarra | Servicio Navarro de Salud - Osasunbidea | Imatinib 400 mg | 5,415,200 | 0.0057 | CIPLA EUROPE | 0.0014 | 30/06/2017 |
| Murcia | Servicio Murciano de Salud | IMATINIB 100 MG COMPRIMIDOS RECUBIERTOS/CAPSULAS | 4,200,000 | 0.0075 | ACCORD HEALTHCARE | 0.0016 | 18/02/2018 |
| Murcia | Servicio Murciano de Salud | IMATINIB 400 MG COMPRIMIDOS RECUBIERTOS/CAPSULAS | 14,280,000 | 0.0075 | ACCORD HEALTHCARE | 0.0015 | 18/02/2018 |
| Cataluña | Consorci de Salut i Atenció Social de Catalunya | IMATINIB 400 MG 30 COMPRIMIDOS/CAPSULAS | 24,015,200 | 0.1184 | ACCORD HEALTHCARE | 0.0015 | 10/07/2018 |
| Cataluña | Consorci de Salut i Atenció Social de Catalunya | IMATINIB 400 MG 30 COMPRIMIDOS/CAPSULAS | 24,015,200 | 0.1184 | CIPLA EUROPE | 0.0013 | 10/07/2018 |
| Cataluña | Consorci de Salut i Atenció Social de Catalunya | IMATINIB 400 MG 30 COMPRIMIDOS/CAPSULAS | 24,015,200 | 0.1184 | KERN PHARMA | 0.0031 | 10/07/2018 |
| Cataluña | Consorci de Salut i Atenció Social de Catalunya | IMATINIB 100 MG 60 COMPRIMIDOS/CAPSULAS | 2,823,600 | 0.1184 | ACCORD HEALTHCARE | 0.0026 | 10/07/2018 |
| Cataluña | Consorci de Salut i Atenció Social de Catalunya | IMATINIB 100 MG 60 COMPRIMIDOS/CAPSULAS | 2,823,600 | 0.1184 | CIPLA EUROPE | 0.0012 | 10/07/2018 |
| Cataluña | Consorci de Salut i Atenció Social de Catalunya | IMATINIB 100 MG 60 COMPRIMIDOS/CAPSULAS | 2,823,600 | 0.1184 | KERN PHARMA | 0.0015 | 10/07/2018 |
| Cataluña | Consorci de Salut i Atenció Social de Catalunya | IMATINIB 100 MG COM (indicació GIST) | 1,400,400 | 0.0544 | NOVARTIS FARMACEUTICA | 0.0544 | 10/07/2018 |
| Cataluña | Consorci de Salut i Atenció Social de Catalunya | IMATINIB 400 MG COM (indicació GIST) | 22,269,600 | 0.0544 | NOVARTIS FARMACEUTICA | 0.0544 | 10/07/2018 |
| Andalucía | Plataforma de Logística Sanitaria de Córdoba | IMATINIB 100MG, COMPRIMIDOS-Forma farmacéutica:COMPRIMIDOS | 2,200,000 | 0.0055 | ACCORD HEALTHCARE | 0.0016 | 26/07/2018 |
| Andalucía | Plataforma de Logística Sanitaria de Córdoba | IMATINIB 400MG, COMPRIMIDOS-Forma farmacéutica:COMPRIMIDOS | 21,600,000 | 0.0058 | ACCORD HEALTHCARE | 0.0013 | 26/07/2018 |
| Madrid | Hospital Clínico San Carlos | GLIVEC 100 MG | 540,000 | 0.0566 | NOVARTIS FARMACEUTICA | 0.0544 | 30/07/2018 |
| Madrid | Hospital Clínico San Carlos | GLIVEC 400 MG | 3,120,000 | 0.0566 | NOVARTIS FARMACEUTICA | 0.0544 | 30/07/2018 |
| Canarias | Servicio Canario de la Salud | IMATINIB - IMATINIB 400 MG 30 CÁPSULAS | 19,480,000 | 0.1184 | CIPLA EUROPE | 0.0015 | 10/08/2018 |
| Canarias | Servicio Canario de la Salud | IMATINIB - IMATINIB 100 MG 60 CÁPSULAS | 2,650,000 | 0.1184 | CIPLA EUROPE | 0.0015 | 10/08/2018 |
| Cataluña | Institut Català de la Salut (ICS) | IMATINIB 100 mg comp (EFG) | 2,616,000 | 0.0015 | ACCORD HEALTHCARE | 0.0014 | 12/12/2018 |
| Cataluña | Institut Català de la Salut (ICS) | IMATINIB 400 mg comp (EFG) | 12,120,000 | 0.0015 | ACCORD HEALTHCARE | 0.0014 | 12/12/2018 |
| Comunidad Valenciana | Generalitat Valenciana. Conselleria de Sanidad Universal y Salud Pública | Imatinib 100 MG COMPRIMIDOS, CÁPSULAS | 16,568,000 | 0.0090 | ACCORD HEALTHCARE | 0.0021 | 20/02/2019 |
| Comunidad Valenciana | Generalitat Valenciana. Conselleria de Sanidad Universal y Salud Pública | Imatinib 100 MG COMPRIMIDOS, CÁPSULAS | 16,568,000 | 0.0090 | CIPLA EUROPE | 0.0035 | 20/02/2019 |
| Comunidad Valenciana | Generalitat Valenciana. Conselleria de Sanidad Universal y Salud Pública | Imatinib 100 MG COMPRIMIDOS, CÁPSULAS | 16,568,000 | 0.0090 | SANDOZ FARMACEUTICA | 0.0089 | 20/02/2019 |
| Comunidad Valenciana | Generalitat Valenciana. Conselleria de Sanidad Universal y Salud Pública | Imatinib 100 MG COMPRIMIDOS, CÁPSULAS | 16,568,000 | 0.0090 | TEVA PHARMA | 0.0070 | 20/02/2019 |
| Comunidad Valenciana | Generalitat Valenciana. Conselleria de Sanidad Universal y Salud Pública | Imatínib 400 MG COMPRIMIDOS, CÁPSULAS | 76,275,200 | 0.0091 | ACCORD HEALTHCARE | 0.0025 | 20/02/2019 |
| Comunidad Valenciana | Generalitat Valenciana. Conselleria de Sanidad Universal y Salud Pública | Imatínib 400 MG COMPRIMIDOS, CÁPSULAS | 76,275,200 | 0.0091 | CIPLA EUROPE | 0.0029 | 20/02/2019 |
| Comunidad Valenciana | Generalitat Valenciana. Conselleria de Sanidad Universal y Salud Pública | Imatínib 400 MG COMPRIMIDOS, CÁPSULAS | 76,275,200 | 0.0091 | KERN PHARMA | 0.0088 | 20/02/2019 |
| Comunidad Valenciana | Generalitat Valenciana. Conselleria de Sanidad Universal y Salud Pública | Imatínib 400 MG COMPRIMIDOS, CÁPSULAS | 76,275,200 | 0.0091 | SANDOZ FARMACEUTICA | 0.0091 | 20/02/2019 |
| Comunidad Valenciana | Generalitat Valenciana. Conselleria de Sanidad Universal y Salud Pública | Imatínib 400 MG COMPRIMIDOS, CÁPSULAS | 76,275,200 | 0.0091 | TEVA PHARMA | 0.0050 | 20/02/2019 |
| Murcia | Servicio Murciano de Salud | IMATINIB 100MG 60 COMPRIMIDOS RECUBIERTOS | 3,000,000 | 0.0907 | NOVARTIS FARMACEUTICA | 0.0114 | 13/05/2019 |
| Murcia | Servicio Murciano de Salud | IMATINIB 400MG 30 COMPRIMIDOS RECUBIERTOS | 28,800,000 | 0.0906 | NOVARTIS FARMACEUTICA | 0.0114 | 13/05/2019 |
| Andalucía | Plataforma de Logística Sanitaria de Granada | IMATINIB 100MG, COMPRIMIDOS | 1,296,000 | 0.0024 | CIPLA EUROPE | 0.0012 | 31/05/2019 |
| Madrid | Hospital Universitario de Getafe | IMATINIB 100 MG. COMP. | 474,000 | 0.0066 | TEVA PHARMA | 0.0055 | 27/01/2020 |
Table S XI.
Tenders identified for the Imatinib drug between years 2017 and 2021.
| ORGANISM | BATCH DATA | AWARD DATA | |||||
|---|---|---|---|---|---|---|---|
| Region | Convening body | Product requested by the agency | Volume for tender’s duration (mg) | Maximum bid price (€/mg) | Awardee | Award price (€/mg) | Award date |
| Madrid | Hospital Universitario de Getafe | IMATINIB 400 MG. COMP. | 4,020,000 | 0.0067 | TEVA PHARMA | 0.0014 | 27/01/2020 |
| Andalucía | Plataforma de Logística Sanitaria de Jaén | IMATINIB 400MG, COMPRIMIDOS | 1,400,000 | 0.0170 | TEVA PHARMA | 0.0013 | 12/03/2020 |
| Asturias | Servicio de Salud del Principado de Asturias (Sespa) | IMATINIB 100 MG | 1,438,000 | 0.0022 | CIPLA EUROPE | 0.0012 | 15/05/2020 |
| Asturias | Servicio de Salud del Principado de Asturias (Sespa) | IMATINIB 400 MG | 12,252,000 | 0.0022 | CIPLA EUROPE | 0.0012 | 15/05/2020 |
| Cataluña | Institut Català d’Oncologia (ICO) | IMATINIB 100 mg comprimits/caps | 4,140,000 | 0.0024 | CIPLA EUROPE | 0.0011 | 21/05/2020 |
| Cataluña | Institut Català d’Oncologia (ICO) | IMATINIB 400 mg comprimits/caps | 43,272,000 | 0.0015 | CIPLA EUROPE | 0.0011 | 21/05/2020 |
| Asturias | Servicio de Salud del Principado de Asturias (Sespa) | GLIVEC 100 mg/60 comprimidos | 432,000 | 0.0114 | NOVARTIS FARMACEUTICA | 0.0114 | 07/07/2020 |
| Asturias | Servicio de Salud del Principado de Asturias (Sespa) | GLIVEC 400 mg/30 comprimidos | 4,176,000 | 0.0114 | NOVARTIS FARMACEUTICA | 0.0114 | 07/07/2020 |
| Cataluña | Consorci Hospital Clínic de Barcelona (HCB) | IMATINIB MESILATO 100 MG COMP o CAPS (generico) | 3,438,600 | 0.0012 | ACCORD HEALTHCARE | 0.0011 | 16/12/2020 |
| Cataluña | Consorci Hospital Clínic de Barcelona (HCB) | IMATINIB 100 MG COMP (original) | 357,100 | 0.0114 | NOVARTIS FARMACEUTICA | 0.0114 | 16/12/2020 |
| Cataluña | Consorci Hospital Clínic de Barcelona (HCB) | IMATINIB 400 MG COMP/CAPSULAS ORIGINAL | 2,028,000 | 0.0114 | NOVARTIS FARMACEUTICA | 0.0114 | 16/12/2020 |
| País Vasco | Osakidetza-S.v.s. | IMATINIB (DOE) | 3,150,000 | 0.0114 | NOVARTIS FARMACEUTICA | 0.0058 | 16/03/2021 |
| País Vasco | Osakidetza-S.v.s. | IMATINIB (DOE) | 12,600,000 | 0.0114 | NOVARTIS FARMACEUTICA | 0.0058 | 16/03/2021 |
| País Vasco | Osakidetza-S.v.s. | IMATINIB (DOE) | 6,000,000 | 0.0040 | ACCORD HEALTHCARE | 0.0009 | 16/03/2021 |
| País Vasco | Osakidetza-S.v.s. | IMATINIB (DOE) | 24,000,000 | 0.0040 | ACCORD HEALTHCARE | 0.0012 | 16/03/2021 |
| Andalucía | Plataforma de Logística Sanitaria de Sevilla | IMATINIB 400MG - ORAL | 12,000,000 | 0.0012 | ACCORD HEALTHCARE | 0.0012 | 13/04/2021 |
| Andalucía | Plataforma de Logística Sanitaria de Sevilla | IMATINIB 100MG - ORAL | 2,500,000 | 0.0019 | ACCORD HEALTHCARE | 0.0010 | 13/04/2021 |
Table S XII.
Tenders identified for the Erlotinib drug between years 2017 and 2021.
| ORGANISM | BATCH DATA | AWARD DATA | |||||
|---|---|---|---|---|---|---|---|
| Region | Convening body | Product requested by the agency | Volume for tender’s duration (mg) | Maximum bid price (€/mg) | Awardee | Award price (€/mg) | Award date |
| Extremadura | Servicio Extremeño de Salud | Erlotinib 100 mg comprimido | 640,700 | 0.4914 | ROCHE FARMA | 0.4914 | 03/04/2017 |
| Extremadura | Servicio Extremeño de Salud | Erlotinib 150 mg comprimido | 774,450 | 0.4036 | ROCHE FARMA | 0.4036 | 03/04/2017 |
| Asturias | Gerencia Atención Sanitaria Área IV - Hospital Universitario Central de Asturias | ERLOTINIB 100MG 30 COMP | 72,000 | 0.4914 | ROCHE FARMA | 0.4914 | 13/06/2017 |
| Asturias | Gerencia Atención Sanitaria Área IV - Hospital Universitario Central de Asturias | ERLOTINIB 150MG 30 COMP | 108,000 | 0.4036 | ROCHE FARMA | 0.4036 | 13/06/2017 |
| Castilla la Mancha | Gerencia de Atencion Integrada de Albacete | ERLOTINIB 100 MG COMPRIMIDO | 12,000 | 0.1442 | ROCHE FARMA | 0.1442 | 10/01/2019 |
| Castilla la Mancha | Gerencia de Atencion Integrada de Albacete | ERLOTINIB 150 MG COMPRIMIDO | 100,800 | 0.3407 | ROCHE FARMA | 0.3407 | 10/01/2019 |
| Comunidad Valenciana | Generalitat Valenciana. Conselleria de Sanidad Universal y Salud Pública | Erlotinib 25 MG COMPRIMIDOS | 134,750 | 0.5540 | ROCHE FARMA | 0.5540 | 20/02/2019 |
| Comunidad Valenciana | Generalitat Valenciana. Conselleria de Sanidad Universal y Salud Pública | Erlotinib 100 MG COMPRIMIDOS | 1,080,000 | 0.4906 | ROCHE FARMA | 0.4906 | 20/02/2019 |
| Comunidad Valenciana | Generalitat Valenciana. Conselleria de Sanidad Universal y Salud Pública | Erlotinib 150 MG COMPRIMIDOS | 3,775,800 | 0.4030 | ROCHE FARMA | 0.4030 | 20/02/2019 |
| Canarias | Servicio Canario de Salud | ERLOTINIB 100 MG COMPRIMIDOS ORAL C/30 | 90,000 | 0.4914 | ROCHE FARMA | 0.4668 | 30/04/2019 |
| Canarias | Servicio Canario de Salud | ERLOTINIB 150 MG COMPRIMIDOS ORAL C/30 | 478,500 | 0.4036 | ROCHE FARMA | 0.3835 | 30/04/2019 |
| Madrid | Hospital General Universitario Gregorio Marañón | ERLOTINIB 100 MG COMP. C/30 | 102,000 | 0.4914 | ROCHE FARMA | 0.4914 | 20/06/2019 |
| Aragón | Servicio Aragonés de Salud | TARCEVA (ERLOTINIB)100 MG COMPRIMIDOS RECUBIERTOS | 900,000 | 0.6325 | ROCHE FARMA | 0.5312 | 01/10/2019 |
| Aragón | Servicio Aragonés de Salud | TARCEVA (ERLOTINIB)150 MG COMPRIMIDOS RECUBIERTOS | 450,000 | 0.6325 | ROCHE FARMA | 0.4363 | 01/10/2019 |
| Aragón | Servicio Aragonés de Salud | TARCEVA (ERLOTINIB)25 MG COMPRIMIDOS RECUBIERTOS | 60,000 | 0.6325 | ROCHE FARMA | 0.6000 | 01/10/2019 |
| Andalucía | Plataforma de Logística Sanitaria de Sevilla | ERLOTINIB 150MG, COMPRIMIDOS | 354,000 | 0.4036 | ROCHE FARMA | 0.4036 | 18/10/2019 |
| Castilla y León | Gerencia Regional de Salud de Castilla y León | ERLOTINIB COMPRIMIDOS ORAL 25 MG | 34,500 | 0.5550 | ROCHE FARMA | 0.5550 | 30/12/2019 |
| Castilla y León | Gerencia Regional de Salud de Castilla y León | ERLOTINIB COMPRIMIDOS ORAL 100 MG | 834,000 | 0.4914 | ROCHE FARMA | 0.4914 | 30/12/2019 |
| Castilla y León | Gerencia Regional de Salud de Castilla y León | ERLOTINIB COMPRIMIDOS ORAL 150 MG | 963,000 | 0.4036 | ROCHE FARMA | 0.4036 | 30/12/2019 |
| Murcia | Servicio Murciano de Salud | ERLOTINIB 100MG 30 COMPRIMIDOS RECUBIERTOS | 840,000 | 0.4914 | ROCHE FARMA | 0.4914 | 11/01/2020 |
| Murcia | Servicio Murciano de Salud | ERLOTINIB 150MG 30 COMPRIMIDOS RECUBIERTOS | 2,070,000 | 0.4036 | ROCHE FARMA | 0.4036 | 11/01/2020 |
| Murcia | Servicio Murciano de Salud | ERLOTINIB 25MG 30 COMPRIMIDOS RECUBIERTOS | 180,000 | 0.5550 | ROCHE FARMA | 0.5550 | 11/01/2020 |
| Madrid | Hospital Universitario la Paz | ERLOTINIB - TARCEVA 100mg compr C/30 - CN 652160 | 150,000 | 0.4914 | ROCHE FARMA | 0.4914 | 10/02/2020 |
| Madrid | Hospital Universitario la Paz | ERLOTINIB - TARCEVA 150mg comp C/30 - CN 652161 | 630,000 | 0.4036 | ROCHE FARMA | 0.4036 | 10/02/2020 |
| Cataluña | Institut Català de la Salut (ICS) | ERLOTINIB 150 mg comp | 51,750 | 0.4036 | SANDOZ FARMACEUTICA | 0.0288 | 23/09/2020 |
| Cataluña | Institut Català de la Salut (ICS) | ERLOTINIB 100 mg comp | 33,000 | 0.4914 | SANDOZ FARMACEUTICA | 0.0351 | 23/09/2020 |
| Andalucía | Plataforma de Logística Sanitaria de Córdoba | ERLOTINIB 150MG, COMPRIMIDOS | 240,000 | 0.1282 | TEVA PHARMA | 0.0333 | 24/09/2020 |
| Madrid | Hospital Universitario Puerta de Hierro | ERLOTINIB 25 MG COMPR | 3,000 | 0.1800 | SANDOZ FARMACEUTICA | 0.0900 | 11/11/2020 |
| Madrid | Hospital Universitario Puerta de Hierro | ERLOTINIB 100 MG COMPR | 510,000 | 0.1867 | SANDOZ FARMACEUTICA | 0.0349 | 11/11/2020 |
| Madrid | Hospital Universitario Puerta de Hierro | ERLOTINIB 150 MG COMPR | 375,000 | 0.0999 | SANDOZ FARMACEUTICA | 0.0286 | 11/11/2020 |
| País Vasco | Osakidetza-S.v.s. | ERLOTINIB (DOE) COMPRIMIDO DE 100MG | 240,000 | 0.1597 | SANDOZ FARMACEUTICA | 0.0350 | 26/11/2020 |
| País Vasco | Osakidetza-S.v.s. | ERLOTINIB (DOE) COMPRIMIDO DE 150MG | 390,000 | 0.1311 | SANDOZ FARMACEUTICA | 0.0287 | 26/11/2020 |
| Cataluña | Consorci Hospital Clínic de Barcelona (HCB) | ERLOTINIB 150 MG COMP REC PELIC | 101,700 | 0.4036 | TARBIS FARMA | 0.0400 | 16/12/2020 |
| Cataluña | Consorci de Salut i Atenció Social de Catalunya | ERLOTINIB 100 MG COMPRIMIDO | 1,749,400 | 0.3187 | ROCHE FARMA | 0.3187 | 29/12/2020 |
| Cataluña | Consorci de Salut i Atenció Social de Catalunya | ERLOTINIB 100 MG COMPRIMIDO | 1,749,400 | 0.3187 | SANDOZ FARMACEUTICA | 0.0317 | 29/12/2020 |
| Cataluña | Consorci de Salut i Atenció Social de Catalunya | ERLOTINIB 100 MG COMPRIMIDO | 1,749,400 | 0.3187 | TARBIS FARMA | 0.0298 | 29/12/2020 |
| Cataluña | Consorci de Salut i Atenció Social de Catalunya | ERLOTINIB 100 MG COMPRIMIDO | 1,749,400 | 0.3187 | TEVA PHARMA | 0.3187 | 29/12/2020 |
Table S XII.
Tenders identified for the Erlotinib drug between years 2017 and 2021.
| ORGANISM | BATCH DATA | AWARD DATA | |||||
| Region | Convening body | Product requested by the agency | Volume for tender’s duration (mg) | Maximum bid price (€/mg) | Awardee | Award price (€/mg) | Award date |
| Cataluña | Consorci de Salut i Atenció Social de Catalunya | ERLOTINIB 150 MG COMPRIMIDO | 2,415,600 | 0.2618 | ROCHE FARMA | 0.2618 | 29/12/2020 |
| Cataluña | Consorci de Salut i Atenció Social de Catalunya | ERLOTINIB 150 MG COMPRIMIDO | 2,415,600 | 0.2618 | SANDOZ FARMACEUTICA | 0.0286 | 29/12/2020 |
| Cataluña | Consorci de Salut i Atenció Social de Catalunya | ERLOTINIB 150 MG COMPRIMIDO | 2,415,600 | 0.2618 | TARBIS FARMA | 0.0212 | 29/12/2020 |
| Cataluña | Consorci de Salut i Atenció Social de Catalunya | ERLOTINIB 150 MG COMPRIMIDO | 2,415,600 | 0.2618 | TEVA PHARMA | 0.2618 | 29/12/2020 |
| Cataluña | Consorci de Salut i Atenció Social de Catalunya | ERLOTINIB 25 MG COMPRIMIDO | 365,550 | 0.3600 | ROCHE FARMA | 0.3600 | 29/12/2020 |
| Cataluña | Consorci de Salut i Atenció Social de Catalunya | ERLOTINIB 25 MG COMPRIMIDO | 365,550 | 0.3600 | SANDOZ FARMACEUTICA | 0.0716 | 29/12/2020 |
| Cataluña | Consorci de Salut i Atenció Social de Catalunya | ERLOTINIB 25 MG COMPRIMIDO | 365,550 | 0.3600 | TARBIS FARMA | 0.0392 | 29/12/2020 |
| Cataluña | Consorci de Salut i Atenció Social de Catalunya | ERLOTINIB 25 MG COMPRIMIDO | 365,550 | 0.3600 | TEVA PHARMA | 0.0392 | 29/12/2020 |
| Cataluña | Institut Català d’Oncologia (ICO) | ERLOTINIB 25 MG | 187,500 | 0.0424 | TARBIS FARMA | 0.0240 | 10/02/2021 |
| Cataluña | Institut Català d’Oncologia (ICO) | ERLOTINIB 100 MG | 435,000 | 0.0356 | TARBIS FARMA | 0.0218 | 10/02/2021 |
| Cataluña | Institut Català d’Oncologia (ICO) | ERLOTINIB 150 MG | 742,500 | 0.0289 | TARBIS FARMA | 0.0162 | 10/02/2021 |
Table S XIII.
Tenders identified for the Gefitinib drug between years 2018 and 2021.
| ORGANISM | BATCH DATA | AWARD DATA | |||||
|---|---|---|---|---|---|---|---|
| Region | Convening body | Product requested by the agency | Volume for tender’s duration (mg) | Maximum bid price (€/mg) | Awardee | Award price (€/mg) | Award date |
| Madrid | Hospital General Universitario Gregorio Marañón | GEFITINIB (IRESSA) 250 MG 30 COMPRIMIDOS RECUBIERTOS | 547,500 | 0.2422 | ASTRAZENECA FARMACEUTICA SPAIN | 0.2422 | 17/05/2018 |
| Madrid | Hospital Clínico San Carlos | GEFITINIB (IRESSA) 250 MG COMP | 600,000 | 0.2422 | ASTRAZENECA FARMACEUTICA SPAIN | 0.2422 | 07/06/2018 |
| Castilla la Mancha | Gerencia de Atención Integrada de Almansa | GEFITINIB - IRESSA 250 MG COMP E/30 | 360,000 | 0.2523 | ASTRAZENECA FARMACEUTICA SPAIN | 0.2523 | 22/01/2019 |
| Canarias | Servicio Canario de Salud | GEFITINIB 250 MG COMPRIMIDOS ORAL C/30 | 1,142,500 | 0.2523 | ASTRAZENECA FARMACEUTICA SPAIN | 0.2523 | 30/04/2019 |
| Murcia | Servicio Murciano de Salud | GEFITINIB 250 MG 30 COMPRIMIDOS RECUBIERTOS | 3,000,000 | 0.2523 | ASTRAZENECA FARMACEUTICA SPAIN | 0.2523 | 13/05/2019 |
| Andalucía | Plataforma de Logística Sanitaria de Jaén | GEFITINIB 250MG COMPRIMIDOS-Forma farmacéutica:COMPRIMIDOS | 812,500 | 0.2422 | ASTRAZENECA FARMACEUTICA SPAIN | 0.2422 | 03/07/2019 |
| País Vasco | Osakidetza-S.v.s. | GEFITINIB COMPRIMIDO DE 250MG | 1,250,000 | 0.0187 | TEVA PHARMA | 0.0120 | 11/09/2019 |
| Asturias | Servicio de Salud del Principado de Asturias (Sespa) | GEFITINIB 250 MG. COMPRIMIDOS RECUBIERTOS CON PELÍCULA | 937,500 | 0.0240 | ACCORD HEALTHCARE | 0.0091 | 05/06/2020 |
| Asturias | Servicio de Salud del Principado de Asturias (Sespa) | GEFITINIB 250 MG. COMPRIMIDOS RECUBIERTOS CON PELÍCULA | 1,260,000 | 0.0240 | ACCORD HEALTHCARE | 0.0091 | 05/06/2020 |
| Cataluña | Institut Català de la Salut (ICS) | GEFITINIB 250 mg comp | 399,375 | 0.2523 | ACCORD HEALTHCARE | 0.0078 | 22/06/2020 |
| Andalucía | Plataforma de Logística Sanitaria de Córdoba | GEFITINIB 250MG, COMPRIMIDOS-Forma farmacéutica:COMPRIMIDOS | 1,300,000 | 0.0202 | TEVA PHARMA | 0.0060 | 24/09/2020 |
| Cataluña | Consorci de Salut i Atenció Social de Catalunya | GEFITINIB 250 MG COMPRIMIDOS RECUBIERTO | 1,957,000 | 0.1600 | ACCORD HEALTHCARE | 0.0077 | 29/12/2020 |
| Cataluña | Consorci de Salut i Atenció Social de Catalunya | GEFITINIB 250 MG COMPRIMIDOS RECUBIERTO | 1,957,000 | 0.1600 | CIPLA EUROPE | 0.0090 | 29/12/2020 |
| Cataluña | Consorci de Salut i Atenció Social de Catalunya | GEFITINIB 250 MG COMPRIMIDOS RECUBIERTO | 1,957,000 | 0.1600 | LABORATORIO REIG JOFRE | 0.0062 | 29/12/2020 |
| Cataluña | Consorci de Salut i Atenció Social de Catalunya | GEFITINIB 250 MG COMPRIMIDOS RECUBIERTO | 1,957,000 | 0.1600 | SANDOZ FARMACEUTICA | 0.0104 | 29/12/2020 |
| Cataluña | Corporació Sanitària Parc Taulí | GEFITINIB 250 MG COMP - GEFITINIB | 240,500 | 0.0200 | TEVA PHARMA | 0.0080 | 26/01/2021 |
Table S XIV.
Tenders identified for the Everolimus drug between years 2017 and 2021.
| ORGANISM | BATCH DATA | AWARD DATA | |||||
|---|---|---|---|---|---|---|---|
| Region | Convening body | Product requested by the agency | Volume for tender’s duration (mg) | Maximum bid price (€/mg) | Awardee | Award price (€/mg) | Award date |
| Castilla y León | Complejo Asistencial Universitario de Salamanca | AFINITOR 5 mg 30 COMP. | 5,250 | 10.9365 | NOVARTIS FARMACEUTICA | 10.9365 | 04/08/2017 |
| Castilla y León | Complejo Asistencial Universitario de Salamanca | AFINITOR 10 mg 30 COMP. | 27,000 | 8.9057 | NOVARTIS FARMACEUTICA | 8.9057 | 04/08/2017 |
| Asturias | Gerencia Atención Sanitaria Área IV - Hospital Universitario Central de Asturias | Everolimus 0,25 mg (60 comp.) (Certican) | 225 | 6.1240 | NOVARTIS FARMACEUTICA | 6.1240 | 08/01/2019 |
| Asturias | Gerencia Atención Sanitaria Área IV - Hospital Universitario Central de Asturias | Everolimus 0,5 mg (60 comp.) (Certican) | 60 | 6.1240 | NOVARTIS FARMACEUTICA | 6.1240 | 08/01/2019 |
| Asturias | Gerencia Atención Sanitaria Área IV - Hospital Universitario Central de Asturias | Everolimus 1 mg (60 com p.) (Certican) | 840 | 6.1242 | NOVARTIS FARMACEUTICA | 6.1242 | 08/01/2019 |
| Asturias | Gerencia Atención Sanitaria Área IV - Hospital Universitario Central de Asturias | Everolimus 5 mg (30 comp.) (Afinitor) | 15,900 | 10.9365 | NOVARTIS FARMACEUTICA | 10.9365 | 08/01/2019 |
| Asturias | Gerencia Atención Sanitaria Área IV - Hospital Universitario Central de Asturias | Everolimus 10 mg (30 comp.) (Afinitor) | 36,600 | 8.9057 | NOVARTIS FARMACEUTICA | 8.9057 | 08/01/2019 |
| Asturias | Gerencia Atención Sanitaria Área IV - Hospital Universitario Central de Asturias | Everolimus 3 mg (30 comp.) (Votubia) | 1,980 | 9.0773 | NOVARTIS FARMACEUTICA | 9.0773 | 08/01/2019 |
| Asturias | Gerencia Atención Sanitaria Área IV - Hospital Universitario Central de Asturias | Everolimus 5 mg (30 comp.) (Votubia) | 1,500 | 9.0777 | NOVARTIS FARMACEUTICA | 9.0777 | 08/01/2019 |
| Andalucía | Plataforma de Logística Sanitaria de Sevilla | EVEROLIMUS 10MG, COMPRIMIDOS-Forma | 124,500 | 8.9057 | NOVARTIS FARMACEUTICA | 8.9057 | 13/02/2019 |
| Andalucía | Plataforma de Logística Sanitaria de Sevilla | EVEROLIMUS 500MCG, COMPRIMIDOS-Forma | 785 | 6.1241 | NOVARTIS FARMACEUTICA | 6.1241 | 13/02/2019 |
| Andalucía | Plataforma de Logística Sanitaria de Sevilla | EVEROLIMUS 750MCG, COMPRIMIDOS-Forma | 2,355 | 6.1241 | NOVARTIS FARMACEUTICA | 6.1241 | 13/02/2019 |
| Comunidad Valenciana | Generalitat Valenciana. Conselleria de Sanidad Universal y Salud Pública | Everolimus 5 MG COMPRIMIDOS (HUERFANO) | 40,200 | 9.0640 | NOVARTIS FARMACEUTICA | 9.0640 | 28/03/2019 |
| Comunidad Valenciana | Generalitat Valenciana. Conselleria de Sanidad Universal y Salud Pública | Everolimus 10 MG COMPRIMIDOS | 374,920 | 8.8920 | NOVARTIS FARMACEUTICA | 8.8920 | 28/03/2019 |
| Comunidad Valenciana | Generalitat Valenciana. Conselleria de Sanidad Universal y Salud Pública | Everolimus 10 MG COMPRIMIDOS (HUERFANO) | 4,800 | 8.8920 | NOVARTIS FARMACEUTICA | 8.8920 | 28/03/2019 |
| Comunidad Valenciana | Generalitat Valenciana. Conselleria de Sanidad Universal y Salud Pública | Everolimus 2.5 MG COMPRIMIDOS (HUERFANO) | 23,700 | 9.0640 | NOVARTIS FARMACEUTICA | 9.0640 | 28/03/2019 |
| Cataluña | Institut Català de la Salut (ICS) | A-EVEROLIMUS 5 mg comp | 5,775 | 10.9365 | ACCORD HEALTHCARE | 2.6900 | 27/06/2019 |
| Cataluña | Institut Català de la Salut (ICS) | A-EVEROLIMUS 10 mg comp | 32,550 | 8.9057 | ACCORD HEALTHCARE | 2.2200 | 27/06/2019 |
| Extremadura | Servicio Extremeño de Salud | Everolimus (AFINITOR) 10 Mg 1 Comprimido | 51,900 | 8.9058 | ACCORD HEALTHCARE | 4.7000 | 16/10/2019 |
| Extremadura | Servicio Extremeño de Salud | Everolimus (AFINITOR) 5 Mg 1 Comprimido | 20,400 | 10.9365 | ACCORD HEALTHCARE | 4.8400 | 16/10/2019 |
| Murcia | Servicio Murciano de Salud | AFINITOR 10MG COMPRIMIDOS, 30 COMPRIMIDOS-663793 | - | 8.9057 | NOVARTIS FARMACEUTICA | 5.7767 | 28/11/2019 |
| Murcia | Servicio Murciano de Salud | AFINITOR 5MG COMPRIMIDOS, 30 COMPRIMIDOS-663792 | - | 10.9365 | NOVARTIS FARMACEUTICA | 5.7767 | 28/11/2019 |
| Murcia | Servicio Murciano de Salud | CERTICAN 1 MG COMPRIMIDOS, 60 COMPRIMIDOS-700530 | - | 5.6275 | NOVARTIS FARMACEUTICA | 5.6275 | 28/11/2019 |
| Murcia | Servicio Murciano de Salud | CERTICAN 0,75 MG COMPRIMIDOS, 60 COMPRIMIDOS-700529 | - | 5.6276 | NOVARTIS FARMACEUTICA | 5.6276 | 28/11/2019 |
| Murcia | Servicio Murciano de Salud | CERTICAN 0,5 MG COMPRIMIDOS, 60 COMPRIMIDOS-700528 | - | 5.6277 | NOVARTIS FARMACEUTICA | 5.6277 | 28/11/2019 |
| Murcia | Servicio Murciano de Salud | VOTUBIA 10MG COMPRIMIDOS, 30 COMPRIMIDOS-697856 | - | 9.0778 | NOVARTIS FARMACEUTICA | 5.7767 | 28/11/2019 |
| Murcia | Servicio Murciano de Salud | VOTUBIA 5MG COMPRIMIDOS, 30 COMPRIMIDOS-684617 | - | 9.0777 | NOVARTIS FARMACEUTICA | 5.7767 | 28/11/2019 |
| Murcia | Servicio Murciano de Salud | VOTUBIA 2,5MG COMPRIMIDOS, 30 COMPRIMIDOS-684619 | - | 9.0777 | NOVARTIS FARMACEUTICA | 5.7767 | 28/11/2019 |
| Andalucía | Plataforma de Logística Sanitaria de Córdoba | EVEROLIMUS 2MG, COMPRIMIDOS-Forma farmacéutica:COMPRIMIDOS | 2,400 | 9.4560 | NOVARTIS FARMACEUTICA | 5.7767 | 19/12/2019 |
| Andalucía | Plataforma de Logística Sanitaria de Córdoba | EVEROLIMUS 5MG, COMPRIMIDOS | 7,500 | 9.4560 | NOVARTIS FARMACEUTICA | 5.7767 | 19/12/2019 |
| Castilla la Mancha | Gerencia de Atención Integrada de Cuenca | VOTUBIA 5 mg comp c/30 - 684617 | 3,600 | 9.0920 | NOVARTIS FARMACEUTICA | 9.0778 | 13/01/2020 |
| Madrid | Hospital Universitario Fundación Alcorcón | EVEROLIMUS - VOTUBIA 10 MG COMPRIMIDOS 30 COMPRIMIDOS - 697856 | 7,500 | 5.7767 | NOVARTIS FARMACEUTICA | 5.7767 | 02/07/2020 |
| Cataluña | Consorci Hospital Clínic de Barcelona (HCB) | EVEROLIMUS 1 MG COMP | 3,304 | 5.6275 | NOVARTIS FARMACEUTICA | 5.6276 | 16/12/2020 |
| Cataluña | Consorci Hospital Clínic de Barcelona (HCB) | EVEROLIMUS 5 MG COMP/COMP | 1,160 | 5.7767 | NOVARTIS FARMACEUTICA | 5.7767 | 16/12/2020 |
| Cataluña | Consorci Hospital Clínic de Barcelona (HCB) | EVEROLIMUS 10 MG COMP/COMP | 8,660 | 5.7767 | NOVARTIS FARMACEUTICA | 5.7767 | 16/12/2020 |
| Cataluña | Consorci de Salut i Atenció Social de Catalunya | EVEROLIMUS (ANTITUMORAL) 10 MG COMPRIMIDOS | 218,220 | 5.7770 | ACCORD HEALTHCARE | 1.7600 | 29/12/2020 |
| Cataluña | Consorci de Salut i Atenció Social de Catalunya | EVEROLIMUS (ANTITUMORAL) 10 MG COMPRIMIDOS | 218,220 | 5.7770 | MEDICARE PHARMA | 1.6065 | 29/12/2020 |
| Cataluña | Consorci de Salut i Atenció Social de Catalunya | EVEROLIMUS (ANTITUMORAL) 10 MG COMPRIMIDOS | 218,220 | 5.7770 | NOVARTIS FARMACEUTICA | 5.7767 | 29/12/2020 |
| Cataluña | Consorci de Salut i Atenció Social de Catalunya | EVEROLIMUS (ANTITUMORAL) 10 MG COMPRIMIDOS | 218,220 | 5.7770 | REDDY PHARMA IBERIA | 1.6000 | 29/12/2020 |
Table S XIV.
Tenders identified for the Everolimus drug between years 2017 and 2021.
| ORGANISM | BATCH DATA | AWARD DATA | |||||
|---|---|---|---|---|---|---|---|
| Region | Convening body | Product requested by the agency | Volume for tender’s duration (mg) | Maximum bid price (€/mg) | Awardee | Award price (€/mg) | Award date |
| Cataluña | Consorci de Salut i Atenció Social de Catalunya | EVEROLIMUS (ANTITUMORAL) 5 MG COMPRIMIDO | 66,310 | 7.0940 | ACCORD HEALTHCARE | 2.0400 | 29/12/2020 |
| Cataluña | Consorci de Salut i Atenció Social de Catalunya | EVEROLIMUS (ANTITUMORAL) 5 MG COMPRIMIDO | 66,310 | 7.0940 | MEDICARE PHARMA | 1.4666 | 29/12/2020 |
| Cataluña | Consorci de Salut i Atenció Social de Catalunya | EVEROLIMUS (ANTITUMORAL) 5 MG COMPRIMIDO | 66,310 | 7.0940 | NOVARTIS FARMACEUTICA | 5.7767 | 29/12/2020 |
| Cataluña | Consorci de Salut i Atenció Social de Catalunya | EVEROLIMUS (ANTITUMORAL) 5 MG COMPRIMIDO | 66,310 | 7.0940 | REDDY PHARMA IBERIA | 1.4540 | 29/12/2020 |
| Cataluña | Corporació Sanitària Parc Taulí | EVEROLIMUS 5 MG COMP. - EVEROLIMUS | 2,655 | 5.7767 | ACCORD HEALTHCARE | 2.4000 | 12/01/2021 |
| Canarias | Servicio Canario de la Salud | EVEROLIMUS 0.25 MG ORAL-CERTICAN 0,25MG 60 COMPRIMIDOS | 2,430 | 5.6273 | NOVARTIS FARMACEUTICA | 5.6273 | 21/01/2021 |
| Canarias | Servicio Canario de la Salud | EVEROLIMUS 0.5 MG ORAL-CERTICAN 0,5MG 60 COMPRIMIDOS | 7,020 | 5.6277 | NOVARTIS FARMACEUTICA | 5.6277 | 21/01/2021 |
| Canarias | Servicio Canario de la Salud | EVEROLIMUS 0.75 MG ORAL-CERTICAN 0,75MG 60 COMPRIMIDOS | 3,510 | 5.6367 | NOVARTIS FARMACEUTICA | 5.6276 | 21/01/2021 |
| Canarias | Servicio Canario de la Salud | EVEROLIMUS 1 MG ORAL-CERTICAN 1MG 60 COMPRIMIDOS | 12,840 | 5.6275 | NOVARTIS FARMACEUTICA | 5.6275 | 21/01/2021 |
| Madrid | Hospital Universitario Puerta de Hierro | CERTICAN - EVEROLIMUS 0,25 MG COMPR DISPERS - CN 700527 | 1,500 | 5.6276 | NOVARTIS FARMACEUTICA | 5.6276 | 09/02/2021 |
| Madrid | Hospital Universitario Puerta de Hierro | CERTICAN - EVEROLIMUS 0,50 MG COMPR - CN 700528 | 4,000 | 5.6276 | NOVARTIS FARMACEUTICA | 5.6276 | 09/02/2021 |
| Madrid | Hospital Universitario Puerta de Hierro | CERTICAN - EVEROLIMUS 0,75 MG COMPR - CN 700529 | 9,000 | 5.6276 | NOVARTIS FARMACEUTICA | 5.6276 | 09/02/2021 |
| Madrid | Hospital Universitario Puerta de Hierro | CERTICAN - EVEROLIMUS 1 MG COMPR - CN 700530 | 46,000 | 5.6276 | NOVARTIS FARMACEUTICA | 5.6276 | 09/02/2021 |
| Madrid | Hospital Universitario Puerta de Hierro | VOTUBIA - EVEROLIMUS 2,5 MG COMPR - CN 684619 | 4,000 | 5.7767 | NOVARTIS FARMACEUTICA | 5.7767 | 09/02/2021 |
| Madrid | Hospital Universitario Puerta de Hierro | VOTUBIA - EVEROLIMUS 5 MG COMP DISPERS - CN 684617 | 21,000 | 5.7767 | NOVARTIS FARMACEUTICA | 5.7767 | 09/02/2021 |
| Madrid | Hospital Universitario Puerta de Hierro | VOTUBIA - EVEROLIMUS 3 MG COMP DISPERS - CN 702016 | 3,000 | 5.7767 | NOVARTIS FARMACEUTICA | 5.7767 | 09/02/2021 |
| País Vasco | Osakidetza-S.v.s. | EVEROLIMUS (DOE) COMPRIMIDO DE 5MG | 20,000 | 3.4660 | LABORATORIO STADA | 1.3280 | 21/05/2021 |
| País Vasco | Osakidetza-S.v.s. | EVEROLIMUS (DOE) COMPRIMIDO DE 10MG | 56,000 | 3.4660 | LABORATORIO STADA | 1.3290 | 21/05/2021 |
References
- 1.SEOM. Las cifras del cáncer en España 2020. [Accessed January; 2022 ];Soc Española Oncol Médica. 2020 :1. Online [Google Scholar]
- 2.AESEG. Ventajas de los Medicamentos Genéricos. [Accessed January; 2022 ]; Online [Google Scholar]
- 3.Cheung WY, Kornelsen EA, Mittmann N et al. The economic impact of the transition from branded to generic oncology drugs. Curr Oncol. 2019;26(2):89–93. doi: 10.3747/co.26.4395. PubMed [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Bristol-Myers settles Revlimid patent suit with India’s Cipla. S&P Global Market Intelligence. Online [Google Scholar]